Highland Capital Management Lowers stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Highland Capital Management reduced its stake in Merck & Co. by 0.55% during the most recent quarter end. The investment management company now holds a total of 594,938 shares of Merck & Co. which is valued at $34,976,405 after selling 3,289 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on Jul 18, 2016.Merck & Co. makes up approximately 2.92% of Highland Capital Management’s portfolio.

Other Hedge Funds, Including , Stewart Patten Co reduced its stake in MRK by selling 840 shares or 7.9% in the most recent quarter. The Hedge Fund company now holds 9,799 shares of MRK which is valued at $576,083. Merck & Co. makes up approx 0.11% of Stewart Patten Co’s portfolio.Btr Capital Management Inc reduced its stake in MRK by selling 2,985 shares or 3.33% in the most recent quarter. The Hedge Fund company now holds 86,526 shares of MRK which is valued at $5,106,765. Merck & Co. makes up approx 1.14% of Btr Capital Management Inc’s portfolio.Gillespie Robinson Grimm Inc reduced its stake in MRK by selling 966 shares or 7.84% in the most recent quarter. The Hedge Fund company now holds 11,350 shares of MRK which is valued at $675,893. Merck & Co. makes up approx 0.11% of Gillespie Robinson Grimm Inc’s portfolio.Franklin Street Advisors Inc Nc boosted its stake in MRK in the latest quarter, The investment management firm added 13,976 additional shares and now holds a total of 94,623 shares of Merck & Co. which is valued at $5,634,800. Merck & Co. makes up approx 1.04% of Franklin Street Advisors Inc Nc’s portfolio.Summit Financial Wealth Advisors boosted its stake in MRK in the latest quarter, The investment management firm added 4,063 additional shares and now holds a total of 11,838 shares of Merck & Co. which is valued at $702,585. Merck & Co. makes up approx 0.29% of Summit Financial Wealth Advisors’s portfolio.

Merck & Co. opened for trading at $59 and hit $59.119 on the upside on Wednesday, eventually ending the session at $58.79, with a gain of 0.22% or 0.13 points. The heightened volatility saw the trading volume jump to 64,76,048 shares. Company has a market cap of $162,732 M.

On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *